Cryofocus Medtech (Shanghai) Co (HKSE:06922) Debt-to-Equity : 0.05 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co Debt-to-Equity?

Cryofocus Medtech (Shanghai) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$3.02 Mil. Cryofocus Medtech (Shanghai) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$7.95 Mil. Cryofocus Medtech (Shanghai) Co's Total Stockholders Equity for the quarter that ended in Jun. 2023 was HK$224.69 Mil. Cryofocus Medtech (Shanghai) Co's debt to equity for the quarter that ended in Jun. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cryofocus Medtech (Shanghai) Co's Debt-to-Equity or its related term are showing as below:

HKSE:06922' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.05 Max: 0.05
Current: 0.07

During the past 4 years, the highest Debt-to-Equity Ratio of Cryofocus Medtech (Shanghai) Co was 0.05. The lowest was 0.01. And the median was 0.05.

HKSE:06922's Debt-to-Equity is ranked better than
74.96% of 707 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs HKSE:06922: 0.07

Cryofocus Medtech (Shanghai) Co Debt-to-Equity Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co Debt-to-Equity Chart

Cryofocus Medtech (Shanghai) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.01

0.05

0.07

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			0.05	N/A	0.05	0.05	0.07

Competitive Comparison of Cryofocus Medtech (Shanghai) Co's Debt-to-Equity

For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryofocus Medtech (Shanghai) Co's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's Debt-to-Equity falls into.

Cryofocus Medtech (Shanghai) Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cryofocus Medtech (Shanghai) Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.833	+	8.866)	/	267.044
	=	0.05

Cryofocus Medtech (Shanghai) Co's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.022	+	7.952)	/	224.69
	=	0.05

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cryofocus Medtech (Shanghai) Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, CHN, 200120

Website

https://www.cryofocus.com

Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Headlines

No Headlines